Exclusive Overseas Authorization for Two Biologics: BIO-THERA Strikes a $6 Million Deal

BIO-THERA Pharmaceuticals, a leading biopharmaceutical company, has recently announced a major milestone in its global expansion strategy. In a groundbreaking move, the company has signed an exclusive authorization and commercialization agreement with SteinCares, granting them the exclusive distribution and sales rights for two investigational biologic drugs. This strategic partnership aims to tap into the Latin American market, with a particular focus on Brazil. The deal, valued at an impressive $6 million, marks a significant step forward for BIO-THERA in its mission to provide innovative treatment options to patients worldwide.

On March 18th, BIO-THERA Pharmaceuticals officially inked the agreement with SteinCares, a renowned player in the Latin American healthcare landscape. As per the terms of the agreement, SteinCares will assume the responsibility of submitting the marketing applications and driving commercialization efforts for the two biologic drugs in Brazil and other Latin American regions. BIO-THERA, on the other hand, will oversee the research, development, production, and commercial supply of the drugs, as well as handle the regulatory submissions to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The collaboration with SteinCares holds immense promise for BIO-THERA, as the company brings deep knowledge of the Latin American healthcare system, an established commercial network, and robust marketing capabilities to the table. This expertise positions them perfectly to devise optimal market strategies and maximize the accessibility of the two drugs in the region. Mitchell Waserstein, CEO of SteinCares, expressed excitement about the partnership, highlighting its potential to enhance medical services for Latin American patients. Waserstein also emphasized that the collaboration solidifies SteinCares' leadership position in the biologic drug sector, making them the preferred partner for global biotechnology and pharmaceutical companies seeking entry into the Latin American market. He further pledged a commitment to the highest ethical standards and the goal of providing safe, innovative, and affordable treatment solutions to patients.

Dr. Li Shengfeng, the founder and general manager of BIO-THERA Pharmaceuticals, expressed confidence in the collaboration with SteinCares, emphasizing the opportunity to introduce high-quality biologics to the Latin American market and offer a new therapeutic option for patients in need.

BIO-THERA Pharmaceuticals' partnership with SteinCares marks a significant milestone in the company's efforts to expand its global reach. By granting exclusive distribution and sales rights for two investigational biologic drugs in Brazil and other Latin American regions, BIO-THERA aims to leverage SteinCares' expertise and market presence to maximize patient accessibility and ensure the success of its innovative treatments. With this strategic move, BIO-THERA reaffirms its commitment to advancing healthcare and underscores its position as a key player in the global biopharmaceutical industry.